These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18813808)

  • 1. Activation of Akt-mTOR-p70S6K pathway in angiogenesis in hepatocellular carcinoma.
    Li W; Tan D; Zhang Z; Liang JJ; Brown RE
    Oncol Rep; 2008 Oct; 20(4):713-9. PubMed ID: 18813808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma.
    Li W; Gomez E; Zhang Z
    J Exp Clin Cancer Res; 2007 Dec; 26(4):527-33. PubMed ID: 18365549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of TGF-beta-induced apoptosis by interlukin-4 through Akt activation and p70S6K survival signaling pathways.
    Lin SJ; Chang C; Ng AK; Wang SH; Li JJ; Hu CP
    Apoptosis; 2007 Sep; 12(9):1659-70. PubMed ID: 17624592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
    Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
    Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
    Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
    Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease.
    Chen S; Nakahara T; Uchi H; Takeuchi S; Takahara M; Kido M; Dugu L; Tu Y; Moroi Y; Furue M
    Br J Dermatol; 2009 Aug; 161(2):357-63. PubMed ID: 19438435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Akt as a potential mediator of adaptations that reduce muscle injury.
    Lockhart NC; Baar K; Mazzeo RS; Brooks SV
    Med Sci Sports Exerc; 2006 Jun; 38(6):1058-64. PubMed ID: 16775545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation.
    Sieghart W; Fuereder T; Schmid K; Cejka D; Werzowa J; Wrba F; Wang X; Gruber D; Rasoul-Rockenschaub S; Peck-Radosavljevic M; Wacheck V
    Transplantation; 2007 Feb; 83(4):425-32. PubMed ID: 17318075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
    Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Refeeding and insulin activate the AKT/p70S6 kinase pathway without affecting IRS1 tyrosine phosphorylation in chicken muscle.
    Duchêne S; Métayer S; Audouin E; Bigot K; Dupont J; Tesseraud S
    Domest Anim Endocrinol; 2008 Jan; 34(1):1-13. PubMed ID: 17029674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation.
    Liu J; Brown RE
    Ann Clin Lab Sci; 2010; 40(3):211-7. PubMed ID: 20689131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of MK-801 on mTOR/p70S6K and translation-related proteins in rat frontal cortex.
    Yoon SC; Seo MS; Kim SH; Jeon WJ; Ahn YM; Kang UG; Kim YS
    Neurosci Lett; 2008 Mar; 434(1):23-8. PubMed ID: 18262357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tum-1, a tumstatin fragment, gene delivery into hepatocellular carcinoma suppresses tumor growth through inhibiting angiogenesis.
    Goto T; Ishikawa H; Matsumoto K; Nishimura D; Kusaba M; Taura N; Shibata H; Miyaaki H; Ichikawa T; Hamasaki K; Nakao K; Maeshima Y; Eguchi K
    Int J Oncol; 2008 Jul; 33(1):33-40. PubMed ID: 18575748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
    Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
    Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma.
    Brown RE; Zhang PL; Lun M; Zhu S; Pellitteri PK; Riefkohl W; Law A; Wood GC; Kennedy TL
    Ann Clin Lab Sci; 2006; 36(3):273-82. PubMed ID: 16951268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
    Zhao X; Li J; Zhuo J; Cai L
    Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.